US Markets

India's Cadila to end late-stage trials of potential COVID-19 vaccine in March

India's Zydus Cadila plans to complete late-stage trials for its potential coronavirus vaccine in March 2021 and could produce up to 100 million doses a year if trials are successful, Chairman Pankaj Patel told Reuters told Reuters.

By Sumit Khanna

AHMEDABAD, India July 17 (Reuters) - India's Zydus Cadila CADI.NS plans to complete late-stage trials for its potential coronavirus vaccine in March 2021 and could produce up to 100 million doses a year if trials are successful, Chairman Pankaj Patel told Reuters.

Cadila's vaccine candidate, dubbed ZyCov-D, is one of dozens being developed around the world to fight the coronavirus.

(Writing by Zeba Siddiqui; Editing by Edmund Blair)

((zeba.siddiqui@tr.com; +91-9769624550; @zebatweets; Reuters Messaging: zeba.siddiqui.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More